Certainly there are some betting on Acadia struggling to get...

Certainly there are some betting on Acadia struggling to get Daybue sales growth back on track. I imagine they should make Q1 guidance but that will mean a need for $100 million quarters the rest of the way to hit the annual and there will no doubt be much attention on the predicted Q2 sales. Currently the numbers sit where Neuren should earn one lot of $50 million for exceeding annual sales of $250 million but not the second for $500 million and I imagine this will stay that way based on Acadia's expectations. The overall value for Neuren shouldn't hinge on minor swings in revenue but the sentiment regarding longer term growth will be affected with these results and could have a significant impact on share price. In concert with this announcement will be the conclusion of the Pitt Hopkins trial and build up to those results about a month later I guess. The success of Phelan Mcdermid should build hopes so will be interesting how these two key things play out and where we're sitting when it's all settled and done. Everything else is basically noise